Opiant Pharmaceuticals Interest Expense 2011-2026 | OPNT

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Opiant Pharmaceuticals

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
2.13 M	131 K	-	145 K	20 K	-11.9 K	28.2 K	160 K	553 K	61.4 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
2.13 M	-11.9 K	357 K

Quarterly Interest Expense Opiant Pharmaceuticals

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	391 K	401 K	421 K	-	547 K	542 K	537 K	-	-	-	-	-	112 K	123 K	122 K	-	20 K	6 K	5 K	877	7 K	12 K	7 K	5.49 K	-2 K	-11.3 K	-2.24 K	19.4 K	5.83 K	27.6 K	4.1 K	6.24 K	8.21 K	132 K	8.21 K	109 K	126 K	255 K	126 K	3 K	145 K	3.73 K	145 K	-	13.5 K	-	13.5 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
547 K	-11.3 K	116 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
BioNTech SE BNTX	14.2 M	$ 95.5	-3.88 %	$ 27.2 B	Germany
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Athira Pharma ATHA	1.24 M	-	-	$ 269 M	USA
ACADIA Pharmaceuticals ACAD	1.82 M	$ 22.35	0.72 %	$ 3.7 B	USA
Galapagos NV GLPG	1.03 M	$ 28.39	-0.13 %	$ 2.69 B	Belgium
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 3.5	5.42 %	$ 5.76 M	Israel
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
InflaRx N.V. IFRX	2.69 K	$ 1.97	-7.51 %	$ 152 M	Germany
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Allakos ALLK	8 K	-	-	$ 28.6 M	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Arcutis Biotherapeutics ARQT	443 K	$ 23.42	-0.3 %	$ 2.98 B	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	48 K	-	10.36 %	$ 9.8 M	USA
Applied Therapeutics APLT	-27 K	-	-	$ 8.42 M	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
Innate Pharma S.A. IPHA	440 K	$ 1.4	-2.1 %	$ 235 M	France
CRISPR Therapeutics AG CRSP	86.6 M	$ 52.38	-2.24 %	$ 4.71 B	Schweiz
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	36.7 M	$ 1.64	4.46 %	$ 436 M	Britain
Inventiva S.A. IVA	12.2 M	$ 5.42	2.85 %	$ 138 M	France
Atreca BCEL	3 K	-	-11.76 %	$ 5.79 M	USA